Telemedicine Follow-Up for Early Laryngeal Cancer: a Randomized Controlled Trial Comparing Care Close to Home Versus Standard of Care

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Apr 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether follow-up care for patients with early laryngeal cancer (a type of throat cancer) can be effectively done through Telemedicine, which allows patients to have virtual check-ups instead of going to a specialized cancer center. The trial aims to find out if patients are just as satisfied with Telemedicine follow-ups as they are with in-person visits, and if the safety outcomes, such as cancer recurrence and complications, are similar between the two methods.

To participate in this trial, you need to have had surgery for early-stage glottic cancer and live at least 45 minutes away from a specialized cancer center. Participants will be randomly assigned to either the Telemedicine follow-up group or the standard in-person follow-up group. Throughout the trial, participants will have their follow-ups guided by clinical guidelines and will complete surveys about their experiences at the beginning, 6 months, and 12 months after their treatment. This study is actively recruiting patients and aims to provide valuable insights into the effectiveness of Telemedicine for cancer care, especially for those living farther away from specialized facilities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients who underwent TOLS for early stage glottic squamous cell carcinoma (T1 or carcinoma-in-situ)
• • a one-way travel time to the HNOC of ≥45 minutes (intervention group) or \< 30 minutes (control group)
• • within 2 years postoperatively
• • can speak and write Dutch
• Exclusion Criteria:
• • Patients will be excluded if they continue to undergo follow-up for other (head and neck) cancers in the HNOC.